Cargando…
Sarcoidosis mortality in Sweden: a population-based cohort study
We aimed to investigate sarcoidosis mortality in a large, population-based cohort, taking into account disease heterogeneity. Individuals with incident sarcoidosis (n=8207) were identified from the Swedish National Patient Register using International Classification of Disease codes (2003‒2013). In...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886843/ https://www.ncbi.nlm.nih.gov/pubmed/29467203 http://dx.doi.org/10.1183/13993003.01815-2017 |
_version_ | 1783312183795384320 |
---|---|
author | Rossides, Marios Kullberg, Susanna Askling, Johan Eklund, Anders Grunewald, Johan Arkema, Elizabeth V. |
author_facet | Rossides, Marios Kullberg, Susanna Askling, Johan Eklund, Anders Grunewald, Johan Arkema, Elizabeth V. |
author_sort | Rossides, Marios |
collection | PubMed |
description | We aimed to investigate sarcoidosis mortality in a large, population-based cohort, taking into account disease heterogeneity. Individuals with incident sarcoidosis (n=8207) were identified from the Swedish National Patient Register using International Classification of Disease codes (2003‒2013). In a subset, cases receiving treatment ±3 months from diagnosis were identified from the Prescribed Drug Register. Nonsarcoidosis comparators from the general population were matched to cases 10:1 on birth year, sex and county. Individuals were followed for all-cause death in the Cause of Death Register. Adjusted mortality rates, rate differences and hazard ratios (HRs) were estimated, stratifying by age, sex and treatment status. The mortality rate was 11.0 per 1000 person-years in sarcoidosis versus 6.7 in comparators (rate difference 2.7 per 1000 person-years). The HR for death was 1.61 (95% CI 1.47‒1.76), with no large variation by age or sex. For cases not receiving treatment within the first 3 months, the HR was 1.13 (95% CI 0.94‒1.35). The HR was 2.34 (95% CI 1.99‒2.75) for those receiving treatment. Individuals with sarcoidosis are at a higher risk of death compared to the general population. For the majority, the increased risk is small. However, patients whose disease leads to treatment around diagnosis have a two-fold increased risk of death. Future interventions should focus on this vulnerable group. |
format | Online Article Text |
id | pubmed-5886843 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-58868432018-04-09 Sarcoidosis mortality in Sweden: a population-based cohort study Rossides, Marios Kullberg, Susanna Askling, Johan Eklund, Anders Grunewald, Johan Arkema, Elizabeth V. Eur Respir J Original Articles We aimed to investigate sarcoidosis mortality in a large, population-based cohort, taking into account disease heterogeneity. Individuals with incident sarcoidosis (n=8207) were identified from the Swedish National Patient Register using International Classification of Disease codes (2003‒2013). In a subset, cases receiving treatment ±3 months from diagnosis were identified from the Prescribed Drug Register. Nonsarcoidosis comparators from the general population were matched to cases 10:1 on birth year, sex and county. Individuals were followed for all-cause death in the Cause of Death Register. Adjusted mortality rates, rate differences and hazard ratios (HRs) were estimated, stratifying by age, sex and treatment status. The mortality rate was 11.0 per 1000 person-years in sarcoidosis versus 6.7 in comparators (rate difference 2.7 per 1000 person-years). The HR for death was 1.61 (95% CI 1.47‒1.76), with no large variation by age or sex. For cases not receiving treatment within the first 3 months, the HR was 1.13 (95% CI 0.94‒1.35). The HR was 2.34 (95% CI 1.99‒2.75) for those receiving treatment. Individuals with sarcoidosis are at a higher risk of death compared to the general population. For the majority, the increased risk is small. However, patients whose disease leads to treatment around diagnosis have a two-fold increased risk of death. Future interventions should focus on this vulnerable group. European Respiratory Society 2018-02-22 /pmc/articles/PMC5886843/ /pubmed/29467203 http://dx.doi.org/10.1183/13993003.01815-2017 Text en Copyright ©ERS 2018 http://creativecommons.org/licenses/by/4.0/ This ERJ Open article is open access and distributed under the terms of the Creative Commons Attribution Licence 4.0. |
spellingShingle | Original Articles Rossides, Marios Kullberg, Susanna Askling, Johan Eklund, Anders Grunewald, Johan Arkema, Elizabeth V. Sarcoidosis mortality in Sweden: a population-based cohort study |
title | Sarcoidosis mortality in Sweden: a population-based cohort study |
title_full | Sarcoidosis mortality in Sweden: a population-based cohort study |
title_fullStr | Sarcoidosis mortality in Sweden: a population-based cohort study |
title_full_unstemmed | Sarcoidosis mortality in Sweden: a population-based cohort study |
title_short | Sarcoidosis mortality in Sweden: a population-based cohort study |
title_sort | sarcoidosis mortality in sweden: a population-based cohort study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886843/ https://www.ncbi.nlm.nih.gov/pubmed/29467203 http://dx.doi.org/10.1183/13993003.01815-2017 |
work_keys_str_mv | AT rossidesmarios sarcoidosismortalityinswedenapopulationbasedcohortstudy AT kullbergsusanna sarcoidosismortalityinswedenapopulationbasedcohortstudy AT asklingjohan sarcoidosismortalityinswedenapopulationbasedcohortstudy AT eklundanders sarcoidosismortalityinswedenapopulationbasedcohortstudy AT grunewaldjohan sarcoidosismortalityinswedenapopulationbasedcohortstudy AT arkemaelizabethv sarcoidosismortalityinswedenapopulationbasedcohortstudy |